Eliapixant

DB21465InvestigationalSmall molecule

Eliapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist. Eliapixant is under investigation in clinical... Eliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix...

Mechanism: Pharmacologically active on P2X purinoceptor 3
Curator reviewed
Formula / weight: C₂₂H₂₁F₃N₄O₃S · 478.49 g/mol (avg)
Code names: BAY-1817080

Resolves to

Compound

UNII9GH7E6347BCAS1948229-21-7ChEMBLCHEMBL5095224

Structure

InChIKeyGTQPEQGDLVSFJO-CXAGYDPISA-NSMILESC[C@@H](NC(=O)C1=CC(=CC(O[C@@H]2CCOC2)=C1)C1=NC=C(C)S1)C1=CN=C(N=C1)C(F)(F)F

Targets

P56373P2RX3

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eliapixant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account